What do CRISPR Therapeutics (NASDAQ: CRSP), Bluebird Bio (NASDAQ: BLUE), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs developing gene therapies," you're right. And because of that, they share one big risk that investors need to know about: manufacturing. 

Most of the time, investors in biopharma businesses don't need to worry about manufacturing, because companies can price their medicines according to the costs they anticipate. But for the types of gene therapies that are hitting the market now and in the near future, it isn't that simple. Here's why. 

Let's look at Bluebird's manufacturing process as an example, with the understanding that the other gene therapy stocks mentioned above face largely the same set of issues because they need to make their gene therapies in more or less the same way.

Continue reading

Source Fool.com